Alfentanil reduces the febrile response to interleukin-2 in humans

Citation
C. Negishi et al., Alfentanil reduces the febrile response to interleukin-2 in humans, CRIT CARE M, 28(5), 2000, pp. 1295-1300
Citations number
61
Categorie Soggetti
Aneshtesia & Intensive Care
Journal title
CRITICAL CARE MEDICINE
ISSN journal
00903493 → ACNP
Volume
28
Issue
5
Year of publication
2000
Pages
1295 - 1300
Database
ISI
SICI code
0090-3493(200005)28:5<1295:ARTFRT>2.0.ZU;2-5
Abstract
Objective: Manifestation of intraoperative fever is impaired by volatile an esthetics and muscle relaxants. Opioids are common anesthetic adjuvants and remain the dominant treatment for postoperative surgical pain and sedation of critically ill patients. The effect of opioids on normal thermoregulato ry control is well established. However, the extent to which these drugs mi ght inhibit fever remains unknown. Accordingly, we tested the hypothesis th at relatively low plasma concentrations of the mu-receptor agonist alfentan il reduce fever magnitude. Design: Prospective, randomized, crossover study. Setting: Outcomes Research Laboratory, at the Department of Anesthesia and Perioperative Care, University of California, San Francisco. Patients: Eight healthy male volunteers, aged 25-31 yrs, each studied on th ree separate days. Intervention: Each volunteer was given an intravenous injection of 30 IU/g interleukin (IL)-2, followed 2 hrs later by 70 IU/g. One hour after the sec ond dose, the volunteers were randomly assigned to three doses of alfentani l: a) none (control); b) a target plasma concentration of 100 ng/mL; and c) a target concentration of 200 ng/mL, Opioid administration continued for 5 hrs. Methods and Main Results: Alfentanil significantly reduced the febrile resp onse to pyrogen, decreasing integrated tympanic membrane temperatures from 7.5 +/- 2.2 degrees C hr on the control day, to 4.9 +/- 1.5 degrees C hr wi th 100 ng/mL alfentanil, and to 5.1 +/- 1.7 degrees C.hr with 200 ng/mL alf entanil (p = .011). Peak temperatures were also significantly reduced from 38.5 +/- 0.4 degrees C on the control day, to 38.0 +/- 0.4 degrees C on the 100 ng/mL-alfentanil day and 38.0 +/- 0.6 degrees C on the 200-ng/mL day ( p = .019). Plasma cytokine concentrations increased after IL-2 administrati on, roughly in proportion to the elevation in core temperature. However, cy tokine concentrations did not differ significantly among the treatment grou ps. Conclusion: Alfentanil significantly reduced the febrile response to IL-2 a dministration. However, the reduction was comparable at plasma concentratio ns near 100 and 200 ng/mL. These data indicate that concentrations of opioi ds commonly observed in critical care patients significantly inhibit the ma nifestation of fever.